Wednesday, January 25, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Industry News

Arcturus Awarded $63.2M to Advance Self-amplifying mRNA Vaccine for Pandemic Influenza Response

by Global Biodefense Staff
August 31, 2022
Arcturus Awarded $63.2M to Advance Self-amplifying mRNA Vaccine for Pandemic Influenza Response

Credit: Russell Toof,, modified

$63.2 Million base award to fund development from preclinical stage through Phase 1 over three-year period.

A lower-dose, freeze-dried, pandemic influenza vaccine candidate will use Arcturus’ STARR™ self-amplifying mRNA vaccine platform technology which demonstrated favorable safety and efficacy against SARS-CoV-2 infection combined with a stable cold chain profile that may help support U.S. government pandemic preparedness goals.

During the early stages of a pandemic influenza outbreak, rapidly developing and distributing vaccines is essential to curbing the spread of disease and helping to save lives. As part of ongoing efforts to bolster pandemic preparedness, the Biomedical Advanced Research and Development Authority (BARDA) is partnering with Arcturus Therapeutics Holdings, Inc. to develop a self-amplifying messenger RNA (samRNA) vaccine against pandemic influenza based on the company’s platform technology and using modern production practices to ensure rapid production.

The award to Arcturus is for an initial three years to support preclinical, manufacturing, nonclinical safety studies, along with development and regulatory support for Arcturus’ self-amplifying mRNA vaccine platform technology for rapid pandemic influenza response through Phase 1 clinical studies.

“We are very pleased to have won this substantial award from the BARDA and look forward to working with the U.S. government to support the development of our proprietary self-amplifying mRNA vaccine technology for rapid pandemic influenza response. Arcturus’ next generation mRNA platform has been administered to over 10,000 individuals globally demonstrating favorable safety, strong immunogenicity, and protection against SARS-COV-2 infection,” said Joseph Payne, President and CEO of Arcturus Therapeutics. “Our lyophilized vaccines have the potential to provide safe and effective protection against disease with the specific advantage of rapid scale-up, lower doses, and easier transport and storage. These are qualities that are essential to a rapid response against pandemic influenza and are consistent with strategic objectives of the U.S. government’s National Strategy for Pandemic Influenza.”

Supporting Pandemic Influenza Countermeasure Capacity Building

Beginning in 2005, the U.S. Department of Health and Human Services—guided by the National Strategy for Pandemic Influenza (2005), the National Strategy for Pandemic Influenza Implementation Plan (2006), and the Department of Health and Human Services’ Pandemic Influenza Plan (2017)—began to develop sufficient domestic manufacturing surge capacity to provide pandemic influenza vaccine for the entire country and established a pre-pandemic influenza vaccine stockpile to expedite vaccination of the critical workforce. Additionally, in alignment with the second goal in BARDA’s 2022-2026 Strategic Plan, this program aims to enhance our response posture by leveraging a diverse portfolio of proven medical countermeasure technologies while continuing to identify opportunities for product development to address gaps in preparedness.

To achieve these strategic goals and to provide more vaccines sooner, BARDA is supporting the development of additional production platform technologies and adjuvants for the manufacturing of seasonal and pandemic influenza vaccines. This contract with Arcturus supports the non-clinical efficacy studies and pre-clinical development, early-stage clinical development, drug product manufacturing, and all associated regulatory and quality assurance activities for a samRNA-based pandemic influenza vaccine to enhance U.S. and global pandemic preparedness.

Arcturus’ vaccine candidate uses samRNA. samRNA is designed to make many copies of the viral protein within the cell, thereby enabling lower doses than conventional mRNA vaccines. Utilizing nucleic acid and recombinant-based technologies – which include mRNA-based platforms – for seasonal and pandemic influenza vaccine development offers further options for meeting domestic vaccine manufacturing surge capacity goals. These technologies may make vaccines available much sooner than egg- and cell-based technologies.

Arcturus has used the samRNA platform technology in their leading lyophilized COVID-19 vaccine candidate, ARCT-154, which is currently in late-stage clinical trials. The lyophilized vaccine formulation is stable in standard refrigerators, thereby simplifying cold-chain storage and reducing distribution risks.

This project has been supported in whole or in part with federal funds from the Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA), under Contract Number: 75A50122C00007.

Sources: BARDA, Arcturus Therapeutics Holdings, Inc.

Tags: AwardsEditor PickInfluenzamRNAPandemic

Related Posts

DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
NISTCHO: New Living Reference Material for Producing Monoclonal Antibodies
Medical Countermeasures

NISTCHO: New Living Reference Material for Producing Monoclonal Antibodies

January 12, 2023
Load More

Latest News

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023
Biodefense Headlines – 17 January 2023

Biodefense Headlines – 17 January 2023

January 17, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are okay with it.OkPrivacy policy